159 related articles for article (PubMed ID: 22050341)
1. Romidepsin in the treatment of T-cell lymphoma: profile report.
Yang LP
BioDrugs; 2011 Dec; 25(6):393-5. PubMed ID: 22050341
[No Abstract] [Full Text] [Related]
2. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
4. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
[TBL] [Abstract][Full Text] [Related]
5. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
6. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
Hronek J; Reed M
Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin for the treatment of T-cell lymphomas.
McGraw AL
Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
[TBL] [Abstract][Full Text] [Related]
9. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
Zinzani PL; Pellegrini C; Cerciello G; Monaco F; Volpetti S; Peli A; Angelucci E; Corradini P; Cox MC; Guarini A; Musso M; Bresciani P; Amato G; Billio A; Caparrotti G; Figuera A; Nassi L; Gaudio F; Grossi A; Onida F; Merli M; Rigacci L; Argnani L
Leuk Lymphoma; 2016 Oct; 57(10):2370-4. PubMed ID: 26732313
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
13. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
16. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
O'Connor OA; Falchi L; Lue JK; Marchi E; Kinahan C; Sawas A; Deng C; Montanari F; Amengual JE; Kim HA; Rada AM; Khan K; Jacob AT; Malanga M; Francescone MM; Nandakumar R; Soderquist CR; Park DC; Bhagat G; Cheng B; Risueño A; Menezes D; Shustov AR; Sokol L; Scotto L
Blood; 2019 Oct; 134(17):1395-1405. PubMed ID: 31471376
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
Frye R; Myers M; Axelrod KC; Ness EA; Piekarz RL; Bates SE; Booher S
Clin J Oncol Nurs; 2012 Apr; 16(2):195-204. PubMed ID: 22459529
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY; Grant S
Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma.
Bashey S; Krathen M; Abdulla F; Sundram U; Kim YH
J Clin Oncol; 2012 Aug; 30(24):e221-5. PubMed ID: 22753921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
